Objective: Drug shortages are occurring at an increasing rate. From May to October 2016, there was a shortage of a level I critical antiepileptic drug, clobazam. We aimed to study the impact of this shortage on patients with epilepsy. Methods: Adult patients from Calgary's Comprehensive Epilepsy Program who were taking clobazam were approached to participate in the study. Baseline data from the clinic prospective registry included clinical variables and presurvey patient-reported outcomes (PROs) such as the Global Assessment of Severity of Epilepsy, the Global Assessment of Disability Associated with Seizures, and the Quality of Life in Epilepsy questionnaire. We used a mixed-methods cross-sectional questionnaire via telephone. We analyzed quantitative data using descriptive methods and qualitative data using a phenomenological approach. Results: Of the 85 eligible patients, 84% (n = 71) agreed to participate. Participants ranged from 18 to 78 years old, and 59.2% of participants were female.
the CPhA, Canadian Medical Association, and Canadian Society of Hospital Pharmacists, 66% of respondents reported that drug shortages had further increased since 2010. 3, 5 Similarly, in the United States, the prevalence of emergency medicine drug shortages increased from 23 drugs to 123 drugs, or 435%, between 2008 and 2014. 2 Many factors can contribute to drug shortages, such as increases in demand, shortages of raw materials, and issues meeting regulatory body requirements. 6, 7 In addition, generic drug shortages may be more common than brand name drug shortages due to their low profit margins. Low profit margins can make it more difficult for manufacturers to secure the raw materials for these drugs or even deter them from producing the drug altogether. 8 The number of suppliers of a drug can also affect the likelihood of shortages occurring. 9 In May 2016, a shortage of the level I critical antiepileptic drug (AED) clobazam became serious in Canada and lasted until October 2016. 10 This shortage resulted in complete depletion of clobazam in many pharmacies across the country. The cause of this shortage was multifactorial (eg, increased clobazam prescribing, shortage of active ingredient, changes in quality standards). AED shortages can have many serious adverse effects on patients with epilepsy. For example, patients with epilepsy can face treatment interruptions due to shortages and, based on evidence from nonadherence studies, treatment interruptions can result in increased seizures or relapse of previously well-controlled epilepsy. 11 During drug shortages, patients are also often unable to refill their full prescription, which necessitates more frequent refilling. Because medication refilling in patients with epilepsy is associated with increased odds of a seizure-related hospital visit, it implies that drug shortages may cause an increase in seizure-related adverse events. 12 Patients with epilepsy exposed to drug shortages may also be subject to increased costs if they are required to switch to a brand name AED if the generic becomes unavailable. Patients may also receive less effective treatments during shortages if they are required to change medications due to unavailability. Despite these deleterious consequences, few studies have examined drug shortages from the patient perspective. We aimed to study the impact of the clobazam shortage on patients with epilepsy from their perspective, while it was occurring.
| MATERIALS AND METHODS

| Study design
A longitudinal cohort study including a mixed-methods cross-sectional survey was used to determine the impact of the recent clobazam shortage on patients with epilepsy who are taking this medication. The Conjoint Health Research Ethics Board at the University of Calgary (REB16-1067) approved this study.
| Study participants
Patients were identified using Calgary's Comprehensive Epilepsy Program (CEP) clinical database. The CEP is a tertiary care center for adults with epilepsy, and all patient data are collected, stored, and extracted using REDCap electronic capture tools hosted at the University of Calgary's Clinical Research Unit. 13 Alberta patients were eligible if they were seen at the CEP between January 2015 and June 2016, had epilepsy, 14 and were taking clobazam at the time of their last visit. Patients were excluded if they were younger than 18 years or were no longer on clobazam at the time of the questionnaire.
| Baseline data
Participant baseline data were collected from the CEP database from their last visit to the clinic prior to the clobazam shortage. Baseline visit dates (preshortage visit) occurred from November 2014 to June 2016. Baseline data included: seizure frequency per month (continuous variable), the validated Global Assessment of Severity of Epilepsy (GASE), 15 the Global Assessment of Disability Associated with Seizures (GADS), 16 and single-item categorical variables addressing whether the good things about their AEDs outweigh the bad and satisfaction with medication (see the survey in Appendix S1 for details regarding each variable). Baseline data also included the validated Quality of Life in Epilepsy (QOLIE-10-P) questionnaire. 17 The GASE is a single-item 7-point scale regarding overall epilepsy severity. 15 Similarly, the GADS is a
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• There was a shortage of the level I critical antiepileptic drug clobazam in Canada from May to October 2016
• The impact of the shortage on patients related to 6 themes; the first 2 themes were communication/awareness and increased burden
• The other 4 themes were physical impact, psychological impact, health care provider assistance, and policy change
• Recommendations for mitigating the impact of shortages on patients include improving communication and education among key stakeholders single-item 7-point scale regarding seizure-related disability. 16 The QOLIE-10-P includes 10 questions, with varying scaled response options, relevant to quality of life for adults with epilepsy, such as questions regarding daily activities and epilepsy-related concerns. 17 Each participant's demographic, clinical, and medication history were also routinely collected.
| Telephone interview
A mixed-methods telephone survey was conducted between June and August 2016 to determine the impact of the clobazam shortage on patients with epilepsy during the shortage. Research assistants, trained in interview practices to minimize response bias, contacted patients at least 3 times, at varying times of the day. If by the third attempt to contact there was no answer, a voicemail was left. If a patient was incompetent, a caregiver responded on their behalf. The research assistants entered anonymized responses as they were given, directly into the electronic survey form. The 24-item questionnaire based on the data collected in the CEP was developed through expert consultation with 3 epileptologists and an epilepsy health services researcher to compare pre-and during-shortage outcomes (Appendix S1).
The survey included open-ended questions and multiple-choice questions that evaluated patient awareness of the shortage, medication-related variables, seizure control, and coping mechanisms. We also included questions (questions [14] [15] in the qualitative component of the survey relating to anxiety and fear based on the experts' clinical experience. The GASE, 15 GADS, 16 QOLIE-10-P, 17 and aforementioned single-item categorical variables addressing whether the good things about their AEDs outweigh the bad and medication satisfaction, which were the patient-reported outcomes (PROs) collected at baseline, were also administered during the interview. The survey was informally pilot tested on 2 patients to ensure that the content was easy to understand and to test its face validity and usability.
2.5 | Data analysis
| Quantitative analysis
Descriptive statistics were used to describe the demographic characteristics of participants, nonresponders (patients who declined to participate), and nonparticipants (patients we were unable to contact) to determine whether there was any potential for selection bias. The characteristics of these 3 groups were compared using Pearson chisquare test for categorical variables or a 1-way analysis of variance for continuous variables.
Descriptive statistics were also used to describe the responses to the multiple-choice questions (categorical variables). Pre-and during-shortage data were compared using the nonparametric Wilcoxon test, because the data were categorical and not normally distributed. There were limited missing data, as most variables had 0-7 patients missing and only 2 variables, physical and psychological effects of AEDs based on the QOLIE-10-P, had 15 and 20 patients missing, respectively. Therefore, missing data were excluded casewise from analysis. Stata 14 was used for all quantitative analyses. 18 
| Qualitative analysis
As the literature available on the effect of drug shortages on patients with epilepsy was too sparse to inform the development of themes for qualitative analysis, themes were developed inductively from the survey transcripts using a phenomenological approach rather than using a preexisting theme structure. 19 The survey transcripts were open coded independently by 2 analysts with expertise in qualitative analysis.
After coding each open-ended question, the 2 analysts met to arrive at consensus on the coding structure and definitions. Once open coding was complete, the analysts met to identify themes based on the codes. The frequency with which each theme was endorsed and the number of participants that endorsed it were described quantitatively. NVivo 11 was used for all qualitative analysis. 20 3 | RESULTS
| Participant characteristics
Of the 85 eligible patients, 71 agreed to participate, for a response rate of 84% ( Figure 1 ). There were no significant differences in epilepsy duration or demographic characteristics between participants, nonresponders, and patients whom we were unable to contact (Table 1) . Additional epilepsy-related characteristics can be found in Appendix S2. The time between baseline data collection and data collection during the shortage ranged from 1 month to 1.7 years, with a median of 8.2 months. Overall, 50 (70.4%) participants were aware of the clobazam shortage at the time of the survey. Just under 50% (n = 35) found out from their pharmacist. Participants also found out about the shortage from their neurologist or epilepsy specialist, the news, the Internet, and less frequently from staff at the home they lived in.
Twenty-eight participants reported that the clobazam shortage did not affect them. However, of these 28 participants, 21 had some form of medication change or reported that they had a hard time getting their AED. Of the 71 participants, 57 had some type of change to their clobazam (ie, manufacturer or switch to another AED) according to their electronic medical record. In addition, 21 participants reported a hard time getting their medications (Table 2 ).
| Epilepsy and quality of life
There were no statistically significant differences in participants' pre-and during-shortage responses on the GASE, responses on the GADS, and seizure frequency per month (Table 3 ). There were also no statistically significant differences in participants' pre-and during-shortage responses on epilepsy-related quality of life distress and fear of having a seizure according to the QOLIE-10-P (Table 3) . 17 However, for the no medication change subgroup, overall quality of life based on the QOLIE-10-P 17 worsened significantly (Table 3 ).
| Medication satisfaction
Medication satisfaction and whether the good things about their AEDs outweighed the bad improved during the shortage compared to preshortage for the subgroup of participants who had no medication change ( Table 3 ). The psychological effects of AEDs and the physical effects of AEDs (based on the QOLIE) were not different between the 2 periods for either subgroup (Table 3) .
| Qualitative results
Qualitative analysis revealed 6 themes: (1) communication and awareness, (2) burden on patients and caregivers, (3) physical impact of the shortage, (4) psychological impact of the shortage, (5) health care provider assistance in navigating the shortage, and (6) policy change (Table 4) .
| Communication and awareness
Participants expressed a desire for information about the drug shortage. Many participants discussed the importance of receiving advanced notice about drug shortages so that they could mentally prepare for the consequences.
"I think just having my pharmacist tell me that there is a shortage so that I know in advance is helpful. If I went to the pharmacist to refill my prescription and they didn't have it without any warning, then I would have a fullblown panic attack."
Participants also wanted to know their alternatives or have a plan in place for when a drug shortage arises.
"I just think doctors need to come up with a plan-if they know there is a shortage they should let us know about it and what the plan is if I am not able to get medication."
Furthermore, participants brought up the issue of unawareness; they mentioned that certain health care providers were unaware of the shortage or indicated that they themselves were unaware.
"It would have been helpful to have information because the pharmacist didn't know anything about it. Pharmacists don't get much info about it themselves. . ." Reported increased side effects 7 (9.9) [headaches, n = 2; dizziness, n = 1; joint pain, n = 1; tremor, n = 1; low energy, n = 1; worsened memory, n = 1; breakthrough seizures, n = 1]
Reported hard time getting medications 21 (29.6) [not able to get seizure medication, n = 10; had to call many pharmacists, n = 10; more travel, n = 6; only able to get small supply, n = 5; other, n = 2] Denominator is 28 (ie, those who reported that they were not impacted).
| Burden on patients and caregivers
Participants emphasized the increased financial and time burden that the clobazam shortage imposed on them and their caregivers. The increased time burden manifested itself in many ways. Many participants indicated that they had to invest time in locating supply by calling many pharmacies or that they had to drive further to pick up their medications.
"Had to call 15 pharmacies-one knew of a different pharmacy that had clobazam and transferred my prescription. I didn't contact the doctor yet, but the pharmacist said you may have to get a substitute. Pharmacy also transferred me to another pharmacy that had supply."
Participants also brought up the need for increased caregiver monitoring as an example of increased time burden. "We've had to switch to another medicationname brand and generic-and now we have to keep an eye on him in case the generic doesn't work even though they say it's the same thing as the brand name."
The issue of increased financial burden resulted from having to pay up front for medication without receiving the full prescription and increased gas costs from having to drive further distances to find supply.
"I live on AISH [Assured Income for the Severely Handicapped] and . . . when they don't have [Frisium] I have to drive around everywhere looking for it and it costs me gas, but I don't have the money . . . Sometimes I wasn't able to make phone calls to all the pharmacies, so my mom had to do it or I wouldn't have been able to do it-so the shortage has affected me health wise and financially. . ."
| Physical impact of the shortage
The physical impact of the shortage related to side effects from changes in medication and seizure frequency. Some of the side effects outlined by participants were mood swings, dizziness, tremors, side pain, and headaches.
"He [patient] talks to himself and that seems to be going up the more that the drug is unavailable. You can tell the change in the brands."
In terms of changes in seizure frequency, there were mixed responses from participants; some experienced increased seizures as a result of the shortage, whereas others did not experience a change.
| Psychological impact of the shortage
The psychological impact of the shortage manifested as fear and anxiety, as well as frustration. Participants' fear and anxiety related to the possibility of not being able to get their clobazam supply in the future and the potential consequences if they were not able to get their supply.
"[The shortage] has caused mental anguish. She [patient] has to have her meds. Without it, her seizures become out of control and it's dangerous. We've been able to get the medication so far, but we were under duress."
For example, some participants worried that if they were unable to get their supply they may have more seizures or have their driving privileges revoked. Participants' expressions of frustration pertained to trying to find supply and switching medications. "Anxious from the time I heard it on the news and contacted all the pharmacies and they were all short, so I worried about not being able to get a supply, after phoning every pharmacy in town I didn't have much luck, once the pharmacist was able to find someone with a supply then my worry settled."
T A B L E 4 Qualitative themes
Although some participants noted that their pharmacist was unaware of the shortage, most participants found that their pharmacist was helpful in navigating the shortage.
| Policy change
Many participants endorsed the need for change to prevent, or better handle, future shortages. Some participants pointed out the need to prevent future shortages but did not outline any mechanisms to do so.
"[It would be helpful] to have clobazam all the time instead of switching from one drug to another drug, especially because [patient] is very sensitive to drug changes, which causes her to go behind instead of forward."
Other participants explicitly pointed out the need for policy change and for the government to take responsibility for its role in drug shortages. The government needs to step up and fix this."
| DISCUSSION
Most existing research on the effect of drug shortages is from health care professionals' perspectives, 1, 3, 4, [21] [22] [23] [24] and there is limited research addressing the patient perspective. 25 In this study, we examined the impact of the clobazam shortage from the patient's viewpoint, which provides insight into what patients need to cope with shortages in the future. There is also limited research on the effects of epilepsy drug shortages. Drug shortages can have unique effects on patients with epilepsy that may not be applicable to other chronic conditions. For example, if patients with epilepsy have breakthrough seizures due to an AED shortage, they may lose their driving privileges, are at risk of status epilepticus, and may have injuries due to falls from recurrent seizures, among other deleterious consequences. 26 As a result, the current study fills an important gap in the literature, as it not only addresses drug shortages from the patient's perspective, but also provides some insight on the impact AED shortages have on patients with epilepsy.
The quantitative analysis failed to show any differences during the shortage compared to preshortage in terms of the PROs and clinical variables that we examined for the subgroup of patients who had a medication change during the shortage. We did find that the no medication change subgroup had a significantly worse overall quality of life based on the QOLIE-10-P during the shortage compared to before the shortage. However, the sample size was too small to do a multivariate analysis, so this result must be interpreted with caution. It is possible that the shortage worsened these participants' quality of life by creating fear and anxiety of being unable to obtain clobazam even though these participants had not yet been required to make a medication change. There may also be other factors contributing to their worsened quality of life that were not accounted for here.
Our qualitative analysis yielded 6 important themes related to the impact on patients. A common theme was communication and awareness, which is congruent with the literature. For example, a study surveying surgical patients found that 76% of these patients wanted their doctor to tell them about anesthesia-medication shortages, even if there were only slight differences between the drug in shortage and its substitute. 25 In addition, several studies found that health care providers reported a lack of advanced notice and management information relating to drug shortages, which coincides with our participants' statements that many health care providers had not established a contingency plan due to an inability to anticipate the clobazam shortage. 1, 4, 24 Another commonly endorsed theme in our study, which the literature also supports, was time and financial burden. 3, 23 For example, other surveys note the need for increased patient monitoring, the extra costs of alternative medications, and the extra time associated with obtaining alternative medications. 3, 23 However, these studies identified this burden by asking health care professionals about the effects of drug shortages on patients rather than asking patients themselves.
As in our study, many studies note that drug shortages can have a physical impact on patients. The physical effects outlined in the literature (not for AEDs specifically) included several adverse events, and in some cases even death. 21, 23 The psychological impact of the shortage reported by the majority of participants in our study was not discussed as extensively in the literature. However, this trend is likely a result of most studies not focusing on patients' perspectives.
The mixed-methods design of our study is one of its strengths, as the combination of quantitative and qualitative data provide unique insight into the impact of the clobazam shortage on patients. The qualitative data were collected using open-ended questions rather than forcing participants to fit their answers into categories based on preconceived notions. As a result, the qualitative data identified important themes about the effects of drug shortages on patients. For example, most study participants expressed that the shortage psychologically affected them in terms of fear and frustration. Because only the qualitative analysis uncovered this important impact of the shortage, it is clear that the qualitative components of this study allowed us to gain a more in-depth view on the multifaceted ways in which drug shortages affect patients that would not have been possible using only quantitative methodology. In addition, selection bias was minimized by the high survey response rate and recall bias was minimized because the survey was conducted during the shortage rather than after the shortage was over.
Although the timing of the survey administration minimized recall bias, it is also a limitation, because some participants had picked up their AED prior to the start of the shortage and had not required any refills by the contact date. It is possible that these participants experienced additional effects of the shortage after the study, which may account for the lack of differences before and during the shortage on several questionnaires. The small sample size (<100 patients) may also account for the lack of quantitative differences before and during the shortage, and it is possible that we did not consider other outcome variables that may have demonstrated a significant difference. In addition, the period between the pre-and during-shortage data varied for each participant. This variation is because the participants' last visit to the CEP clinic restricted the timing of the preshortage data collection and the timing of the telephone interview restricted during-shortage data collection. It would have been interesting to investigate the relationship of the time lapse from baseline data collection and questionnaire data collection with questionnaire responses, and to understand whether responses were associated with epilepsy characteristics (eg, seizure frequency). However, such analysis was precluded by the small sample size and heterogeneity of the stratified groups.
We also do not know how long participants were on clobazam relative to the shortage, which may affect the magnitude of impact that participants felt from the shortage. For example, a participant who has been on clobazam for years may have a better understanding of the medication's impact on their seizures and their side effects than a participant who has been on clobazam for a month. In addition, participants who have been on clobazam for years may also experience a greater psychological impact from the shortage than participants who have been on clobazam for a shorter period. Finally, it was also not possible to account for any confounders, such as life stressors, that may have occurred during the time between the pre-and during-shortage periods.
Another possible limitation of this study is that caregivers responded to the telephone survey questions when patients were not competent. Caregiver responses may not accurately capture what the patients themselves would have reported. However, caregiver responses account for only 21% of responses. We also recruited the sample from a tertiary care setting. This sampling method may limit the study's generalizability, because these patients may have more severe epilepsy. However, the demographics of our population are fairly consistent with the general epilepsy population 27 and their disability and severity scores were quite low. Therefore, we believe that the results of this study are likely applicable to other high-income countries. In addition, many of the issues that patients with epilepsy identified in this study when dealing with the clobazam shortage were similar to the literature on drug shortages in general internationally. 1, 3, 4, [21] [22] [23] [24] [25] As a result, these findings could potentially be broadly applicable to drug shortages in the general population without epilepsy. More research is needed to better understand the complex ways that drug shortages affect patients. We were not able to stratify our analysis by sex due to sample size constraints for subgroup analyses. Future research should investigate whether there are any sex-related trends regarding drug shortages. In addition, most existing recommendations for mitigating the impact of drug shortages are not based on the patient experiences. 28, 29 Because patients' perspectives on this issue have not been extensively studied, our study provides novel insight into the issue of drug shortages in persons with epilepsy. To fill this gap, we provide recommendations for reducing the impact of drug shortages on patients based on the issues and suggestions participants raised through our study (Table 5) . Although these recommendations can reduce the impact of drug shortages on patients, prevention is more effective than mitigation, and policy change to avoid future shortages is imperative. Health for work unrelated to this project, and is an Associate Editor of Epilepsia. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.
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